Invention Title:

DONOR-SPECIFIC TOLERANCE-INDUCING REGIMENS FOR XENOTRANSPLANTATION

Publication number:

US20260335367

Publication date:
Section:

Human necessities

Class:

A61K35/26

Inventors:

Assignee:

Applicant:

Smart overview of the Invention

The patent application discusses a novel method for inducing immune tolerance in xenotransplantation, specifically targeting renal xenografts. This approach involves creating composite thymic kidney organoids by injecting macerated thymic tissue into donor pigs. The technique aims to mitigate immune rejection, a significant barrier in xenotransplantation, by fostering donor-specific tolerance in recipients of kidney transplants.

Technical Field

Xenotransplantation, which involves transplanting organs between different species, faces challenges due to complex immune responses. The application focuses on generating composite thymic kidney organoids to induce immune tolerance, specifically targeting T-cell mediated rejection, a major hurdle in xenotransplantation. The use of pigs as donor animals is emphasized due to their anatomical and physiological similarities to humans.

Methodology

The method involves macerating thymic tissue from a donor animal and injecting it into specific locations such as the kidney, lung, or muscle of the donor or recipient. This tissue matures into composite lymphoid tissues, forming organs like the thymo-kidney or thymo-lung. The process can include culturing the tissue for up to 30 days and may involve robotic assistance for precise injections.

Applications and Embodiments

Various embodiments of the method allow for flexibility in tissue injection sites and repeated applications to enhance tolerance induction. Robotic systems like the da Vinci® Xi™ Surgical System are mentioned for performing these procedures. The generated composite organs can then be transplanted into subjects needing kidney transplants, potentially inducing thymopoiesis within a year.

Potential Benefits

This approach offers a promising solution to the shortage of human organ donors by potentially reducing immune rejection in xenotransplantation. By addressing T-cell mediated rejection through donor-specific tolerance, the method could improve the success rates of xenotransplants, making them a viable alternative to human organ transplants.